• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

1998 Fiscal Year Final Research Report Summary

Individual dosage regimen based on population pharmacokinetics and genotyping of drug metabolizing enzymes

Research Project

Project/Area Number 09672323
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field 応用薬理学・医療系薬学
Research InstitutionKYOTO UNIVERSITY

Principal Investigator

HASHIMOTO Yukiya  Graduate School of Medicine, Kyoto University Associate Professor, 医学研究科, 助教授 (90228429)

Co-Investigator(Kenkyū-buntansha) OKUDA Masahiro  Graduate School of Medicine, Kyoto University Instructor, 医学研究科, 助手 (70252426)
YANO Ikuko  Graduate School of Medicine, Kyoto University Instructor, 医学研究科, 助手 (50273446)
Project Period (FY) 1997 – 1998
Keywordsphenytoin / population pharmacokinetics / CYP2C9 / CYP2C19 / genetic polymorphism / non-linear pharmacokinetics / p450 / drug metabolism
Research Abstract

We have estimated the population pharmacokinetic parameters of phenytoin in Japanese patients with epilepsy (Biol. Pharm. Bull., 19, 444, 1996), and examined the effect of cytochrome P450 (CYP) 2C9/19 polymorphisms on the pharmacokinetics of phenytoin (Clin. Pharmacol. Ther., 62, 287, 1997). In this study, we evaluated the phenytoin dosage regimen based on the simple polymerase chain reaction-based genetic test of CYP2C isozymes. The population pharmacokinetic parameters without the information of CYP2C genotypes failed to predict the serum phenytoin concentration in patients with the mutation in CYP2C9 (Ile^<359>*Leu). In contrast, the genotyping of CYP2C9/19 in individual patients was useful in determining which patients are at risk for drug intoxication. In addition, the precision of the predicted serum phenytoin concentrations was improved by the baysian analysis based on the population pharmacokinetic parameters involving the polymorphism of CYP2C subfamily. The genetic test for the CYP2C isozymes will be useful in designing the dosage of phenytoin.

  • Research Products

    (12 results)

All Other

All Publications (12 results)

  • [Publications] 橋本征也: "母集団速度論に基づく薬物体内動態と薬効の解析" 薬物動態. 12. 401-406 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 小谷敦子: "フェニトインの新規母集団パラメータに基づくベイジアン解析法の評価" 病院薬学. 23. 512-518 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Odani, Atsuko: "Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy." Clin. Pharmacol. Ther.62. 287-292 (1997)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Sasa, Hiroaki: "Hepatic extraction of tacrolimus in rats with experimental liver diaeases." Biol. Pharm. Bull.21. 610-614 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Hashimoto, Yukiya: "Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats." Pharm.Res.15. 1609-1613 (1998)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] 橋本征也: "CYP2C サブファミリーの遺伝子診断情報に基づくフェニトイン個別投与設計法の評価" 臨床薬理. 30. 9-16 (1999)

    • Description
      「研究成果報告書概要(和文)」より
  • [Publications] Yukiya Hashimoto: "Pharmacokinetic and pharmacodynamic analysis based on population approach." Xenobio.Metabol.Dispos.14. 401-406 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Atsuko Odani et al.: "Evaluation of the bayesian individual dosage regimen based on the new population pharmacokinetic parameters of phentyoin." Jap.J.Hosp.Pharm.23. 512-518 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Atsuko Odani et al.: "Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy." Clin.Pharmacol.Ther.62. 287-292 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Hiroaki Sasa et al.: "Hepatic extraction of tacrolimus in rats with experimental liver deseases." Biol.Pharm.Bull.21. 610-614 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Yukiya Hashimoto et al.: "Effects of intestinal and hepatic metabolism on the bioavailability of tracrolimus in rats." Pharm.Res.15. 1609-1613 (1998)

    • Description
      「研究成果報告書概要(欧文)」より
  • [Publications] Yukiya Hashimoto et al.: "Evaluation of individual dosage regimen based on genotyping of the CYP2C subfamily." Jap.J.Clin.Pharmacol.Ther.30. 9-16 (1999)

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 1999-12-08  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi